Blood · 2008 · 136 citations · 59 references
MedicineOncologyPharmacologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis RegulationApoptosis ResistanceApoptotic SignalingBcl-2 Family ProteinsApoptosis Signaling In CancerCell Death SensitizationDeath Ligand ResistanceP53-mediated ApoptosisP53-mediated Cell DeathTrail ReceptorsTrail-mediated Apoptosis
Acute myeloid leukemia (AML) cells are relatively resistant to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL). We previously reported that triptolide, a potent anticancer agent from a Chinese herb, decreases XIAP in leukemic cells. We evaluated the combination of triptolide and TRAIL and found synergistic promotion of apoptosis in AML cells. XIAP-overexpressing U937 cells (U937XIAP) were more resistant to TRAIL than U937neo cells, and inhibition of XIAP with the small-molecule inhibitor 1396-11 enhanced TRAIL-induced apoptosis, implying XIAP as a resistance factor in AML. Furthermore, triptolide increased DR5 levels in OCI-AML3, while the DR5 increase was blunted in p53-knockdown OCI-AML3 and p53-mutated U937 cells, confirming a role for p53 in the regulation of DR5. In support of this finding, disruption of MDM2-p53 binding with subsequent increase in p53 levels by nutlin3a increased DR5 levels and sensitized OCI-AML3 cells to TRAIL. The combination of 1396-11 plus nutlin3a plus TRAIL was more effective than either the 1396-11 and TRAIL or nutlin3a and TRAIL combinations in OCI-AML3 cells, further supporting the role of triptolide as a sensitizer to TRAIL-induced apoptosis in part by independent modulation of XIAP expression and p53 signaling. Thus, the combination of triptolide and TRAIL may provide a novel strategy for treating AML by overcoming critical mechanisms of apoptosis resistance.
59
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Séamus J. Martin, Chris Reutelingsperger, Anne J. McGahon et al. · The Journal of Experimental Medicine · 1995 · 2.9K citations · Full text
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger Pai, Sharon Fong et al. · Journal of Clinical Investigation · 1999 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +17
The p53-mdm-2 autoregulatory feedback loop.
J. Henri Bayle, David C. Olson, Arnold J. Levine · Genes & Development · 1993 · 1.8K citations · Full text